trending Market Intelligence /marketintelligence/en/news-insights/trending/p7mte1LfCXZvGvCO8L1IMQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Bausch Health ends constipation drug partnership with Cipher Pharmaceuticals

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Bausch Health ends constipation drug partnership with Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. said Bausch Health Cos Inc. is terminating their partnership for constipation drug Trulance, citing breach of the agreement's certain provisions.

Oakville, Ontario-based Cipher acquired the exclusive Canadian marketing and selling rights to Trulance from Synergy Pharmaceuticals Inc. in February 2018. Bausch Health then bought certain assets of Synergy Pharmaceuticals in March 2019, including Trulance.

Trulance is approved by the U.S. Food and Drug Administration to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.

As part of a strategic review process for its Canadian commercial assets, Cipher was negotiating the sublicensing of Trulance with multiple parties.

Cipher said the termination is without merit and plans on challenging it.